4/20 BDS Analytics

The holiday always stokes robust sales. But this year’s 4/20? It’s gonna be big. We anticipate more than $100 million in sales on pot’s big day, making it the largest day of sales since dispensaries first started selling cannabis legally. The history-making sales projection revolves in part around the thousands of dispensaries now open nationwide.…

Read More
Canada Legal Spending Chart

Our research on the roll-out of adult-use legalization in Canada, published today in the Cannabis Intelligence Briefing titled Canada Leads the Way on Global Cannabis Legalization, is the first research of its kind. The report models each of the 10 Canadian provinces individually. At a countrywide-level, consumer spending is now forecast to grow from $569…

Read More
pharmaceuticals vs dispensaries | BDS Analytics

Epidiolex Approval Queues Up Pharmaceutical Versus Dispensary Cannabinoids Competition Pharmaceutical cannabinoids have been around since the 1980s in synthetic or semi-synthetic form for the treatment of nausea related to cancer, and anorexia related to both cancer and AIDS. The FDA approved GW Pharmaceuticals’ Epidiolex in 2018 marking the first time that the US federal government…

Read More

By Kate Kaye. Published on May 10, 2017 The legal cannabis market is hotboxed with THC-infused candies, calming and energizing beverages and other products that, without the marijuana injection, would seem a lot like the stuff of mainstream packaged goods. But when companies the growing industry need fusty old data, there’s no industry analysis group…

Read More

Celebrated Art and Design Magazine Featuring BDS Analytics’ own Claire Kaufmann By Ellen Shapiro | January 10, 2017 | Communication Arts Magazine Cannabis? You know… grass, pot, reefer, weed. Except not in the formats favored by Cheech & Chong. It’s more like Sanofi and Starbucks. Or vintage wines and microbrews. “Marijuana is a gold-rush opportunity for…

Read More